107 related articles for article (PubMed ID: 11072153)
41. Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence.
Kuo SH; Huang CS; Kuo WH; Cheng AL; Chang KJ; Chia-Hsien Cheng J
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1456-64. PubMed ID: 18692329
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
43. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
44. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
Woodward WA; Strom EA; Tucker SL; Katz A; McNeese MD; Perkins GH; Buzdar AU; Hortobagyi GN; Hunt KK; Sahin A; Meric F; Sneige N; Buchholz TA
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):336-44. PubMed ID: 12957243
[TBL] [Abstract][Full Text] [Related]
45. Postmastectomy radiotherapy in premenopausal Vietnamese and Chinese women with breast cancer treated in an adjuvant hormonal therapy study.
Love RR; Ba Duc N; Cong Binh N; Mahler PA; Thomadsen BR; Hong Long N; Shen TZ; Havighurst TC
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):697-703. PubMed ID: 12788175
[TBL] [Abstract][Full Text] [Related]
46. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
47. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer.
Huxley N; Jones-Hughes T; Coelho H; Snowsill T; Cooper C; Meng Y; Hyde C; Mújica-Mota R
Health Technol Assess; 2015 Jan; 19(2):v-xxv, 1-215. PubMed ID: 25586547
[TBL] [Abstract][Full Text] [Related]
48. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
49. Cost-utility analysis of 21-gene assay for node-positive early breast cancer.
Masucci L; Torres S; Eisen A; Trudeau M; Tyono I; Saunders H; Chan KW; Isaranuwatchai W
Curr Oncol; 2019 Oct; 26(5):307-318. PubMed ID: 31708649
[TBL] [Abstract][Full Text] [Related]
50. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.
Rankins NC; Secord AA; Jewell E; Havrilesky LJ; Soper JT; Myers E
Gynecol Oncol; 2007 Aug; 106(2):388-93. PubMed ID: 17509672
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of apex axillary invasion for locoregional recurrence and effect of postmastectomy radiotherapy on overall survival in node-positive breast cancer patients.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Alagol H
World J Surg; 2004 Mar; 28(3):236-41. PubMed ID: 14961194
[TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of node-negative breast cancer 5 centimeters and larger treated with and without postmastectomy radiotherapy.
Goulart J; Truong P; Woods R; Speers CH; Kennecke H; Nichol A
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):758-64. PubMed ID: 20646860
[TBL] [Abstract][Full Text] [Related]
55. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Candon D; Healy J; Crown J
Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
[TBL] [Abstract][Full Text] [Related]
56. The sequencing of radiation therapy and chemotherapy after mastectomy in premenopausal women with breast cancer.
Cakir S; Gursel B; Meydan D; Yildiz L
Jpn J Clin Oncol; 2003 Nov; 33(11):563-9. PubMed ID: 14711980
[TBL] [Abstract][Full Text] [Related]
57. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis.
Willner J; Kiricuta IC; Kölbl O
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):853-63. PubMed ID: 9128962
[TBL] [Abstract][Full Text] [Related]
58. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Skedgel C; Rayson D; Younis T
Value Health; 2009; 12(5):641-8. PubMed ID: 19490562
[TBL] [Abstract][Full Text] [Related]
59. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?
Monten C; Lievens Y
Radiother Oncol; 2018 Jan; 126(1):132-138. PubMed ID: 29174721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
